TERN-701 Efficacy and Safety - TERN-701 demonstrated a 64% Major Molecular Response (MMR) achievement rate at 24 weeks across all doses in non-T315I CP-CML patients (N=38)[20, 26] - At doses ≥320 mg QD, TERN-701 achieved a 75% MMR rate and a 36% Deep Molecular Response (DMR) rate at 24 weeks[18, 26, 75] - The majority of Treatment-Emergent Adverse Events (TEAEs) were low grade, with Grade 3 AEs less than 10%[18, 26] - No Dose Limiting Toxicities (DLTs) were observed, and the Maximum Tolerated Dose (MTD) was not identified[26, 37] - The study observed no pancreatic toxicity or clinically significant changes in blood pressure[18, 26] Patient Population and Treatment - The CARDINAL study enrolled a predominantly 3L+ refractory CML population (N=63 as of September 13, 2025)[24] - 38% of patients had prior asciminib treatment, with 75% of those discontinuing due to lack of efficacy[26, 33] - 87% of patients remained on treatment with a median treatment duration of 6.1 months[35] Competitive Landscape and Future Development - Asciminib NBRx share in 2L is 52% and in 3L+ is 53%[7] - Asciminib NBRx share of front-line is 22%[7] - TERN-701 is positioned to potentially capture new patients and switch from both Asciminib and Active Site TKIs[103] - Multiple catalysts are planned in 2026, including expanded CARDINAL data, pivotal dose selection, and alignment with regulators for pivotal studies[99, 106]